Search company, investor...
Oxford BioDynamics company logo

Oxford BioDynamics

Founded Year




Market Cap


About Oxford BioDynamics

Oxford Biodynamics (AIM: OBD) is a diagnostics company that develops tools for the early detection of cancers and genetic diseases. It owns a property tool EpiSwitch that provides research and medical analysis services focused on the discovery, evaluation, validation, and monitoring of a novel class of epigenetic biomarkers. The company was founded in 2007 and is based in Oxford, United Kingdom.

Headquarters Location

John Smith Drive, Oxford Business Park South 3140 Rowan Place

Oxford, England, OX4 2WB,

United Kingdom

+44 (0)1865 518 910

Missing: Oxford BioDynamics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Oxford BioDynamics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Oxford BioDynamics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford BioDynamics is included in 2 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Oxford BioDynamics Patents

Oxford BioDynamics has filed 1 patent.

The 3 most popular patent topics include:

  • Genetics
  • Transcription factors
  • Autosomal recessive disorders
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Genetics, Molecular biology, Hybridisation (biology), Biotechnology


Application Date


Grant Date



Related Topics

Transcription factors, Genetics, Molecular biology, Hybridisation (biology), Biotechnology



Latest Oxford BioDynamics News

Prominent oncologist to discuss advantages of Oxford BioDynamics’ EpiSwitch CiRT at the 2022 Liquid Biopsy Virtual Summit

Nov 21, 2022

Dr. Steven Mamus, Medical Director of Oncology/Hematology, Cancer Center of Sarasota (FL, US), to present how OBD’s EpiSwitch® CIRT is transforming the way Immune Checkpoint Inhibitor (ICI) therapy is administered to cancer patients This prominent industry event provides an excellent opportunity to present the unique benefit of CiRT to oncologists, pathologists, clinical lab managers, executives, pharma and biotech R&D professionals, and decision-makers at hospitals and healthcare systems OBD’s EpiSwitch CiRT is the first-of-its-kind precision medicine test that predicts a patient’s most likely response to ICI therapy from blood as liquid biopsy  November 21, 2022 07:00 AM Eastern Standard Time OXFORD, England--( BUSINESS WIRE )--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch 3D genomics platform, announces that prominent medical oncologist, Dr. Steven Mamus, a regular user of EpiSwitch CiRT, will be speaking about OBD’s flagship test at the 2022 Liquid Biopsy Virtual Summit, 6 December 2022. OBD will also have a virtual booth with information and educational materials for the EpiSwitch CiRT. This event, hosted by GenomeWeb and PMLS, will be an exceptional opportunity to present the unique benefit of EpiSwitch CiRT to accurately predict a cancer patient’s most likely response to ICI therapy with a simple blood sample through liquid biopsy. Building on his personal experience, Dr. Mamus will present the unique benefits of CiRT for oncologists in treatment planning and navigating complex decisions such as immune-related adverse events and pseudo-progression. The event is regularly attended by renowned oncologists, pathologists, clinical lab managers, executives, pharmaceutical and biotech R&D professionals, and decision-makers at hospitals and healthcare systems. Liquid biopsies, a key focus topic for this year’s event, offer several advantages over traditional tissue-based testing due to their non-invasive nature, avoiding a needle biopsy or surgical sampling, and capacity to allow continuous patient monitoring. OBD is the commercial pioneer and technological leader in isolating and analyzing 3D genomic biomarkers from a simple blood draw to guide treatment decisions, assess prognosis, and predict therapy response. In addition, the EpiSwitch platform allows researchers to comprehensively examine complex system-wide regulatory interactions between the host immune system and cancer to detect early cancer, predict its response to drugs, and even stratify patients to likely outcomes. Please visit Precision Medicine Leaders’ Summit website, here , for more information. The virtual event is scheduled for December 6, 2022, from 10:00 am to 3:00 pm EST. For more information about CiRT, please visit: Notes for Editors About Oxford BioDynamics Plc Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. In March 2021, the Company launched its first commercial prognostic test, EpiSwitch ® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit . The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases. OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia. For more information, please visit the Company's website, , or follow on Twitter or LinkedIn . About EpiSwitch® The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment. Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice. In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma. Contacts

Oxford BioDynamics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxford BioDynamics Rank

Oxford BioDynamics Frequently Asked Questions (FAQ)

  • When was Oxford BioDynamics founded?

    Oxford BioDynamics was founded in 2007.

  • Where is Oxford BioDynamics's headquarters?

    Oxford BioDynamics's headquarters is located at John Smith Drive, Oxford Business Park South, Oxford.

  • What is Oxford BioDynamics's latest funding round?

    Oxford BioDynamics's latest funding round is PIPE - II.

  • Who are the investors of Oxford BioDynamics?

    Investors of Oxford BioDynamics include Shore Capital, Baden Hill, GL Capital and University of Oxford.

  • Who are Oxford BioDynamics's competitors?

    Competitors of Oxford BioDynamics include Ikonisys, Stage I Diagnostics, Good Start Genetics, Oncoscope, EraGen Biosciences and 11 more.

Compare Oxford BioDynamics to Competitors


Diamics, Inc. is a medical device and diagnostics company. The company is developing, manufacturing, and marketing cost effective cancer diagnostic systems that will increase long-term cancer survival rates through early detection.

Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.


BIOCAM develops and markets systems in the field of photodynamic detection, fluorescence diagnosis and videodermoscopy. With its multifunctional products DYADERM and DermoGenius BIOCAM is leading in skin cancer detection.


Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Stage I Diagnostics Logo
Stage I Diagnostics

Stage I Diagnostics is a cancer biotechnology company focused on providing early stage diagnosis provided by new biomarkers deployed through In-Vitro Diagnostics (IVD). The company's initial focus is the early diagnosis of ovarian cancer. Stage I's core competency is the process of converting newly discovered genes into commercial products which impact clinical decisions. The company's approach is to determine what characteristics new biomarkers should have to achieve the best diagnostic results in targeted diseases and then to discover what genes exist that fit those characteristics. This process has led us to not only discover and patent numerous genes associated with various types of cancer but also clone 4 new genes.


ProteoGenix offers maternal-fetal diagnostics

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.